Concepedia

Beth Overmoyer

BO

Statistics

Publications

90

Citations

8.5K

H-Index

41

Active since

1987

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Massachusetts General Hospital

Harvard University

Dana-Farber Brigham Cancer Center

Beth Overmoyer is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and breast cancer.

ORCID

Top concepts

Publications per year

1987–2024

90

Publications

90

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Kathy D. Miller, Linnea Chap, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2005 · 1.3K citations · Full text

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Sara M. Tolaney, William T. Barry, Chau T. Dang et al. · New England Journal of Medicine · 2015 · 731 citations · Full text

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 620 citations · Full text

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Stephen E. Jones, John K. Erban, Beth Overmoyer et al. · Journal of Clinical Oncology · 2005 · 546 citations · Full text

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations

, , +17

1–5 of 90